7107 A randomized, prospective, Phase 2 study, with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first line treatment in advanced Renal Cell Cancer (RCC): ROSORC Trial (original) (raw)
7107 A randomized, prospective, Phase 2 study, with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first line treatment in advanced Renal Cell Cancer (RCC): ROSORC Trial
Ejc Suppl, 2009
Emilio Bajetta
Giuseppe Procopio
Sergio Bracarda hasn't uploaded this paper.
Let Sergio know you want this paper to be uploaded.
Ask for this paper to be uploaded.